logo
Twitter
Discord
Email
logo
Quest Diagnostics Incorporated

Quest Diagnostics Incorporated

NYSE•DGX
CEO: Mr. James E. Davis
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1996-12-17
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Contact Information
500 Plaza Drive, Secaucus, NJ, 07094, United States
973-520-2700
www.questdiagnostics.com
Market Cap
$19.72B
P/E (TTM)
20.4
35
Dividend Yield
1.8%
52W High
$197.55
52W Low
$148.70
52W Range
57%
5.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$2.82B+13.18%
4-Quarter Trend

EPS

$2.18+8.46%
4-Quarter Trend

FCF

$419.00M+67.60%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Revenue Growth Total net revenues reached $8,229M, marking a strong 13.5% increase for the nine months ended September 30, 2025.
Operating Income Rises Operating income grew 18.7% to $1,170M for the nine months, showing improved operational efficiency compared to prior year.
Net Income Improvement Net income attributable to Quest Diagnostics increased 15.0% to $747M for the nine months period.
Strong Operating Cash Flow Net cash provided by operating activities totaled $1,421M for the nine months, significantly exceeding the prior period.

Risk Factors

Restructuring Charge Incurred Pre-tax charges of $37M were recorded for the Invigorate restructuring program during the nine months ended September 30, 2025.
Asset Exit Impairment Recorded a $29M impairment charge on long-lived assets related to exiting a specific business during the nine months.
Cash Position Reduced Consolidated cash and equivalents decreased by $117M since year-end 2024, ending the quarter at $432M.
Contingent Liability Growth Contingent consideration obligation increased to $114M as of September 30, 2025, reflecting prior acquisition adjustments.

Outlook

Spectra Acquisition Completed Acquired select clinical testing assets from Spectra Laboratories for $34M cash consideration in August 2025.
Corewell Health Venture Planned Signed agreement for a Michigan laboratory testing venture with Corewell Health, expecting facility operation in 2027.
Capital Expenditure Estimate Estimate approximately $500M in capital expenditures planned for 2025 to support diagnostic offerings growth.
Regulatory Impact Assessment Currently assessing impact of OBBBA legislation and enhanced PTC expiration on future revenue streams through 2028.

Peer Comparison

Revenue (TTM)

Labcorp Holdings Inc.LH
$13.77B
+8.3%
Quest Diagnostics IncorporatedDGX
$10.85B
+13.7%
Biogen Inc.BIIB
$9.99B
+3.9%

Gross Margin (Latest Quarter)

Genmab A/SGMAB
93.8%
-2.6 pp
United Therapeutics CorporationUTHR
87.4%
-1.5 pp
Biogen Inc.BIIB
73.4%
-0.7 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
MTD$29.65B36.0-459.7%64.2%
NTRA$27.24B-106.9-22.2%11.2%
BIIB$22.99B14.39.3%22.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
+2.4%
Moderate Growth
4Q Net Income CAGR
+3.3%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 21, 2025|
    Revenue: $2.82B+13.2%
    |
    EPS: $2.18+8.5%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 23, 2025|
    Revenue: $2.76B+15.2%
    |
    EPS: $2.51+22.4%
    Meet
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: Apr 23, 2025|
    Revenue: $2.65B+12.1%
    |
    EPS: $1.97+13.2%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 20, 2025|
    Revenue: $9.87B+6.7%
    |
    EPS: $7.80+2.8%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 23, 2024|
    Revenue: $2.49B+8.4%
    |
    EPS: $2.01+1.0%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 24, 2024|
    Revenue: $2.40B+2.5%
    |
    EPS: $2.05-1.9%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: Apr 24, 2024|
    Revenue: $2.37B+1.5%
    |
    EPS: $1.74-2.8%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 22, 2024|
    Revenue: $9.25B-6.4%
    |
    EPS: $7.59-6.5%
    Miss